Signal Transduction and Targeted Therapy (Feb 2022)

Thrombin induces ACSL4-dependent ferroptosis during cerebral ischemia/reperfusion

  • Qing-zhang Tuo,
  • Yu Liu,
  • Zheng Xiang,
  • Hong-Fa Yan,
  • Ting Zou,
  • Yang Shu,
  • Xu-long Ding,
  • Jin-jun Zou,
  • Shuo Xu,
  • Fei Tang,
  • Yan-qiu Gong,
  • Xiao-lan Li,
  • Yu-jie Guo,
  • Zhao-yue Zheng,
  • Ai-ping Deng,
  • Zhang-zhong Yang,
  • Wen-jing Li,
  • Shu-ting Zhang,
  • Scott Ayton,
  • Ashley I. Bush,
  • Heng Xu,
  • Lunzhi Dai,
  • Biao Dong,
  • Peng Lei

DOI
https://doi.org/10.1038/s41392-022-00917-z
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 15

Abstract

Read online

Abstract Ischemic stroke represents a significant danger to human beings, especially the elderly. Interventions are only available to remove the clot, and the mechanism of neuronal death during ischemic stroke is still in debate. Ferroptosis is increasingly appreciated as a mechanism of cell death after ischemia in various organs. Here we report that the serine protease, thrombin, instigates ferroptotic signaling by promoting arachidonic acid mobilization and subsequent esterification by the ferroptotic gene, acyl-CoA synthetase long-chain family member 4 (ACSL4). An unbiased multi-omics approach identified thrombin and ACSL4 genes/proteins, and their pro-ferroptotic phosphatidylethanolamine lipid products, as prominently altered upon the middle cerebral artery occlusion in rodents. Genetically or pharmacologically inhibiting multiple points in this pathway attenuated outcomes of models of ischemia in vitro and in vivo. Therefore, the thrombin-ACSL4 axis may be a key therapeutic target to ameliorate ferroptotic neuronal injury during ischemic stroke.